■1型糖尿病是儿童最常见的慢性疾病之一。可穿戴技术(胰岛素泵和连续血糖监测设备)使糖尿病管理相对简单,除了教育和后续行动,提高糖尿病患者的生活质量和健康。
■评估可穿戴技术对1型糖尿病儿童和青少年代谢管理和生活质量的影响。
■系统评价和荟萃分析。
■使用系统评价和荟萃分析的首选报告系统进行系统评价和荟萃分析。PubMed,WebofScience,MEDLINE,科克伦图书馆,EBSCO,在2022年7月和2023年7月使用预定关键字搜索了Ulakbim和GoogleScholar。使用JoannaBriggs研究所的随机对照实验和横断面研究关键评估清单评估研究的方法学质量。采用荟萃分析方法汇总数据。
■包括2011年至2022年之间发表的11项研究。纳入研究的总样本量为1,853。荟萃分析显示,使用可穿戴技术的患者的血红蛋白A1C(HbA1c)水平降低具有统计学意义[平均差异(MD):-0.33,Z=2.54,p=0.01]。然而,该技术对生活质量无影响[标准化平均差(SMD):0.44,Z=1.72,p=0.09].亚组分析显示,HbA1c水平下降发生在横断面研究(MD:-0.49,Z=2.54,p=0.01)和12-19岁(MD=0.59,Z=4.40,p<0.001)和4-18岁年龄组(MD:-0.31,Z=2.56,p=0.01)。关于生活质量的亚组分析显示,根据研究设计没有差异。然而,8-12岁和4-18岁年龄组可穿戴技术组的生活质量高于对照组(SMD:1.32,Z=2.31,p=0.02,SMD:1.00,Z=5.76,p<0.001).
■可穿戴技术可有效降低某些年龄组1型糖尿病儿童和青少年的HbA1c水平。然而,它不会影响生活质量。
Type 1 diabetes is one of the most common chronic diseases in children. Wearable technology (insulin pumps and continuous glucose monitoring devices) that makes diabetes management relatively simple, in addition to education and follow-ups, enhances the quality of life and health of individuals with diabetes.
To evaluate the impact of wearable technology on metabolic management and the quality of life in children and adolescents with type 1 diabetes.
Systematic
review and meta-analysis.
The Preferred Reporting System for Systematic Reviews and Meta-Analyses was used to conduct a systematic
review and meta-analysis. PubMed, Web of Science, MEDLINE, Cochrane Library, EBSCO, Ulakbim and Google Scholar were searched in July 2022 and July 2023 using predetermined keywords. The methodological quality of the studies was evaluated using the Joanna Briggs Institute’s Critical Appraisal Checklists for randomized controlled experimental and cross-sectional studies. The meta-analysis method was used to pool the data.
Eleven studies published between 2011 and 2022 were included. The total sample size of the included studies was 1,853. The meta-analysis revealed that the decrease in hemoglobin A1C (HbA1c) level in those using wearable technology was statistically significant [mean difference (MD): -0.33, Z = 2.54, p = 0.01]. However, the technology had no effect on the quality of life [standardized mean difference (SMD): 0.44, Z = 1.72, p = 0.09]. The subgroup analyses revealed that the decrease in the HbA1c level occurred in the cross-sectional studies (MD: -0.49, Z = 2.54, p = 0.01) and the 12-19 (MD = 0.59, Z = 4.40, p < 0.001) and 4-18 age groups (MD: -0.31, Z = 2.56, p = 0.01). The subgroup analyses regarding the quality of life revealed that there was no difference according to the research design. However, the quality of life was higher in the wearable technology group than in the control group in the 8-12 and 4-18 age groups (SMD: 1.32, Z = 2.31, p = 0.02 and SMD: 1.00, Z = 5.76, p < 0.001, respectively).
Wearable technology effectively reduces the HbA1c levels in children and adolescents with type 1 diabetes in some age groups. However, it does not affect the quality of life.